Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
We are very excited to launch our new website! Please take a few moments to click around and explore...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...